# Novo Nordisk's Wegovy pill appears to be expanding the obesity treatment market.

*biotech · news · 2026-04-07 · CNBC*

## Key points

- Novo Nordisk's Wegovy pill has attracted over 600,000 prescriptions within three months of launch.
- The pill is expanding the obesity treatment market by appealing to patients previously deterred by injections.
- Wegovy pill's entry price of $149 per month is among the lowest for GLP-1 therapies.
- Some patients report early weight loss, but effectiveness and tolerability vary widely by individual and dose.
- Lilly's newly approved Foundayo pill may capture market share due to fewer dietary restrictions than Wegovy.

**Companies:** Novo Nordisk
**Countries:** United States, Denmark

[Read the full story on CNBC](https://www.cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html)

---

Canonical: https://newsio.io/n/ca12cf2c-2b50-4685-9f09-6e3f3f04207c/novo-nordisks-wegovy-pill-appears-to-be-expanding-the-obesity-treatment-market
Summarized by Newsio from CNBC. https://newsio.io/how-it-works